// App-Quantinova.ai

OP0003 : EARLY AND SUSTAINED RESPONSES WITH ANIFROLUMAB TREATMENT IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN 2 PHASE 3 TRIALS

Researchers

Presenter

  • E. F. Morand

Principal Investigators

  • R. Furie

  • I. N. Bruce

  • K. Kalunian

  • R. Kalyani

  • G. Abreu

  • L. Pineda

  • R. Tummala

Medical Centers

  • Deakin University, Melbourne, Australia

  • University of Manchester, Manchester, United Kingdom

  • University of California, San Diego, Rheumatology, La Jolla, United States of America

  • BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, United States of America

  • Early RIA, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Locations

  • Australia

  • United States

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • MDX1333

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved